Plain-English translation of NCT06869278 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing LCAR-AIO, a new type of treatment that uses your own immune cells to help fight neurological autoimmune diseases that haven't responded well to other medications. The therapy is designed for people with multiple sclerosis, neuromyelitis optica spectrum disease, MOG-associated disorders, or myasthenia gravis who have experienced relapse or haven't improved with standard treatments. Researchers want to understand whether this medication is safe and whether it helps control these diseases.
Many people with these autoimmune nerve diseases stop responding to standard treatments, leaving them with few options. This medication represents a newer approach that may offer hope for patients whose conditions have become resistant to existing therapies.
If you enroll, you will undergo several stages: first a screening visit to confirm you qualify, then a procedure to collect your immune cells, followed by chemotherapy to prepare your body, and finally an infusion of the treated cells. After that, you'll participate in follow-up visits so doctors can monitor your safety and how well the treatment works. The study involves careful blood work and monitoring throughout.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China